Xoma Corp. deal

XOMA entered into a cross-licensing agreement with M.D. Anderson Cancer Center for technologies relating to recombinant DNA-derived gelonin, a ribosome-inactivating enzyme derived from seeds with potential for use in autoimmune treatments. ...